If you're relying on certain Abbott Laboratories (ABT) glucose sensors to manage your diabetes, the FDA has some urgent news: stop using them immediately.
In December, the U.S. Food and Drug Administration issued a safety alert after Abbott's FreeStyle Libre 3 sensors were linked to seven deaths and 736 serious injuries. The problem? These devices may display inaccurately low glucose levels, which could prompt patients to make treatment decisions that are not just wrong, but potentially life-threatening.
When Your Medical Device Lies to You
Here's why this matters: continuous glucose monitors are supposed to eliminate the guesswork from diabetes management. They provide real-time readings that help patients decide when to eat, when to take insulin, and when to worry. But if the sensor is telling you your blood sugar is dangerously low when it's actually fine, you might eat unnecessary carbohydrates or skip an insulin dose. Do that repeatedly, and you're setting yourself up for serious complications including hypoglycemia, hyperglycemia, or worse.
The FDA's alert specifically covers certain models of the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. Over time, these falsely low readings can skew both immediate treatment decisions and long-term diabetes management strategies. Abbott confirmed the issue in a letter to customers on November 24, urging anyone with affected sensors to stop using them and dispose of them properly.
Which Devices Are Affected?
Not all Abbott glucose monitors are problematic. The company's FreeStyle Libre 14-day, FreeStyle Libre 2, FreeStyle Libre 2 Plus, and Libre Pro sensors are all in the clear. The FreeStyle Libre 3 readers and mobile apps are also safe to continue using. It's specifically certain batches of the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors that are under scrutiny.
Abbott has notified distributors, healthcare providers, and customers to pull the impacted sensors from both clinical and commercial settings. The company advised patients to check whether their devices fall under the recall and to immediately discontinue use if they do.
The Bigger Picture
The FreeStyle Libre 3 system is designed for adults and children aged four and older, and it's meant to replace traditional finger-stick testing in most situations. These sensors provide continuous glucose trends and alerts, connecting with compatible digital devices to help patients make informed therapy decisions throughout the day.
As of November 14, Abbott had reported 736 serious injuries and seven deaths connected to the sensor malfunction. The company acknowledged that undetected inaccuracies could create risks across the spectrum of diabetes complications, from immediate dangers to long-term health consequences.
ABT Price Action: Abbott Laboratories stock traded up 0.38% at $125.88 on Friday.
